ArticleLife (Basel, Switzerland)2026
Targeted Chemical Monitoring and Integrated Preclinical Evaluation of Zishui Qinggan Yin in 4-NQO-Induced Esophageal Precancer: Histopathological and PI3K/AKT/mTOR-Associated Changes.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Esophageal squamous cell carcinoma frequently develops through a prolonged precancerous phase, creating an opportunity for intervention. Zishui Qinggan Yin (ZSQGY) is a multi-component botanical preparation, but its effects in esophageal precancer and its formulation-level chemical profile remain incompletely defined. We monitored a predefined 40-analyte panel by UPLC-Q Exactive/MS in three independently extracted aliquots from the same formulation batch administered to mice. A 4-nitroquinoline-1-oxide model was then evaluated by consensus histopathology, mouse-grouped whole-slide digital pathology, network-based target prioritization, molecular docking, exploratory drug affinity responsive target stability (DARTS), Western blotting, qPCR, and serial-section immunohistochemistry. Signals corresponding to 38 predefined analytes were reported. ZSQGY treatment was associated with a lower-grade lesion pattern in the evaluated mouse-level specimens. Exploratory DARTS was analyzed in two independent
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.